C4 Therapeutics, Inc. (CCCC) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CCCC Hot Sheet
Join SI Premium – FREE
C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q3 EPS of ($0.35), $0.03 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $15.36 million versus the consensus estimate of $5.9 million.
For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Datadog (DDOG) PT Lowered to $285 at Rosenblatt
- B. Riley: 'RIOT a Compelling Buy on Lack of Equity Required'
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
